Systemic sclerosis: hypothesis-driven treatment strategies

Lancet

Volumn 367, Issue 9523, 2006, Pages 1683-1691

  Charles, Christina ^a   Clements, Philip ^a   Furst, Daniel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN TYPE 1; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FLUOROURACIL; GLYCERYL TRINITRATE; GOLD; ILOPROST; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NIFEDIPINE; PLACEBO; PREDNISOLONE; PROSTACYCLIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT RELAXIN; SALAZOSULFAPYRIDINE; SILDENAFIL; SITAXSENTAN; UNIPROST;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD VESSEL INJURY; CLINICAL TRIAL; DIFFUSE SCLERODERMA; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; LOCALIZED SCLERODERMA; LUNG ALVEOLITIS; LUNG FIBROSIS; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RAYNAUD PHENOMENON; REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TREATMENT INDICATION; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 33646572542     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68737-0     Document Type: Review

References (100)

1. Lawrence R., Helmick C., Arnett F., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41 (1998) 778
2. Black C. Scleroderma-clinical aspects. J Intern Med 234 (1993) 115
3. Medsger Jr. T. Systemic sclerosis (scleroderma): clinical aspects. In: Koopman W. (Ed). Arthritis and allied conditions. 14th edn. (2001), Lippincott Williams & Wilkins, Philadelphia, PA, USA 1590-1624
4. LeRoy E., Black C., Fleischmajer R., et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15 (1988) 202
5. Medsger Jr. T. Classification, prognosis. In: Clements P., and Furst D. (Eds). Systemic sclerosis. 2nd edn. (2004), Lippincott Williams & Wilkins, New York, NY, USA 129-150
6. Furst D., and Clements P. Pathogenesis, fusion (summary). In: Clements P., and Furst D. (Eds). Systemic sclerosis (1996), Williams and Wilkins, Baltimore, MD, USA 275-286
7. Clements P., and Medsger Jr. T. Cutaneous involvement in systemic sclerosis. In: Clements P., and Furst D. (Eds). Systemic sclerosis. 2nd edn. (2004), Lippincott Williams & Wilkins, New York, NY, USA 129-150
8. Steen V. Treatment of systemic sclerosis. Am J Clin Dermatol 2 (2001) 315-325
9. Wigley F. Systemic sclerosis: clinical features. In: Klippel J. (Ed). Primer on the rheumatic diseases. 12th edn. (2001), Arthritis Foundation, Atlanta, GA, USA
10. Jacobsen S., Halberg P., and Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 37 (1998) 750-755
11. Wigley F., Wise R., Miller R., et al. Anti-centromere antibody predicts the ischemic loss of digits in patients with systemic sclerosis. Arthritis Rheum 35 (1992) 688-693
12. Steen V., and Medsger Jr. T. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43 (2000) 2437-2444
13. Steen V., Medsger Jr. T., Osial Jr. T., Ziegler G., Shapiro A., and Rodnan G. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 76 (1984) 779-786
14. Steen V., Powell D., and Medsger Jr. T. Clinical correlation and prognosis based on autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31 (1988) 196-203
15. Feghali-Bostcock C., Medsgar Jr. T., and Wright T. Analysis in systemic sclerosis of twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 48 (2003) 1956-1963
16. Arnett F., Cho M., Chatterjee S., et al. Familial occurrence frequencies and relative risks for systemic sclerosis in three US cohorts. Arthritis Rheum 44 (2001) 1359-1362
17. Arnett F., Howard F., Tan J., et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma: association with an Amerindian HLA haplotype. Arthritis Rheum 39 (1996) 1362-1370
18. Mayes M., and Reveille J. Epidemiology, demographics and genetics. In: Clements P., and Furst D. (Eds). Systemic sclerosis. 2nd edn. (2004), Lippincott Williams & Wilkins, Philadelphia, PA, USA 1-15
19. Reveille J., Brady J., MacLeod-St Clair M., et al. HLA-DPB1 alleles and autoantibody subsets in SLE, Sjogren's syndrome and progressive systemic sclerosis: a question of disease relevance. Tissue Antigens 40 (1992) 45-48
20. Reveille J., Owerbach D., Goldstein R., et al. Association of polar amino acids at position 26 of the HLA DQB1 first domain with anticentromere antibody response in systemic sclerosis. J Clin Invest 89 (1992) 1208-1213
21. Artlett C. Michrochimerism and scleroderma: an update. Curr Rheumatol Rep 5 (2003) 154-159
22. Nelson J. Michrochimerism and HLA relationships of pregnancy: implications for autoimmune diseases. Curr Rheumatol Rep 3 (2001) 222-229
23. Christiner P., Artlett C., Conway R., and Jimenez S. Increased numbers of microchimeric cells of fetal origin are associated with dermal fibrosis in mice following injection of vinyl chloride. Arthritis Rheum 43 (2000) 2598-2605
24. Jimenez S., and Artlett C. Microchimerism and systemic sclerosis. Curr Opin Rheumatol 17 (2005) 86-90
25. Selva-O'Callaghan A., Mijares-Boeckh-Behrens T., Prades E., et al. Lack of evidence of foetal microchimerism in female Spanish patients with systemic sclerosis. Lupus 12 (2003) 15-20
26. Hamamdzic D., Harley R., Hazen-Martin D., and LeRoy E. MCMV induces neointima in IFN-gammaR-/- mice: intimal cell apoptosis and persistent proliferation of myofibroblasts. BMC Musculoskelet Disord 2 (2001) 3
27. Ohtsuka T., and Yamazaki S. Increased prevalence of human parvovirus B19 DNA in systemic sclerosis skin. Br J Dermatol 150 (2004) 1091-1095
28. Parks C., Conrad K., and Cooper G. Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect 107 suppl 5 (1999) 793-802
29. Haustein U., and Anderegg U. Silica induced scleroderma-clinical and experimental aspects. J Rheumatol 25 (1998) 1917-1926
30. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheum 14 (2002) 681-685
31. Ihn H., Yamane K., Kubo M., and Tamaki K. Blockade of endogenous transforming growth factor beta signaling previous up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of TGF-beta receptors. Arthritis Rheum 44 (2004) 474-480
32. Leask A., Holmes A., and Abraham D. Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep 4 (2002) 136-142
33. Kucich U., Rosenbloom J., Abrams W., and Rosenbloom J. Transforming growth factor beta stabilizes elastin mRNA by a pathway requiring active Smads, protein kinase, C-delta and p38. Ann J Respir Cell Mol Biol 26 (2002) 183-188
34. Sakkas L., Xu B., Artlett C., et al. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 168 (2002) 3649-3659
35. Tsuji-Yamada J., Nakazawa M., Minami M., and Sasaki T. Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis. J Rheumatol 28 (2001) 1252-1258
36. Luzina I., Atamas S., Wise R., et al. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum 48 (2003) 2262-2274
37. Schachna L., and Wigley F. Targeting mediators of vascular injury in scleroderma. Curr Opin Rheumatol 14 (2002) 686-693
38. LeRoy E. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am 22 (1996) 675-694
39. Herrick A. Treatment of Raynaud's phenomenon: new insights and developments. Curr Rheumatol Rep 5 (2003) 168-174
40. Abraham D., Vancheeswaran E., Dashwood M., et al. Increases levels of endothelin-1 and differential type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 151 (1997) 831-841
41. Philips N., Bashey R., and Jiminez S. Increased alpha 1(I) procollagen gene expression in tight skin (TSK) mice myocardial fibroblasts is due to a reduced interaction of a negative regulatory sequence with AP-1 transcription factor. J Biol Chem 270 (1995) 9313-9321
42. Hitraya E., Varga J., Artlett C., and Jimenez S. Identification of elements in the promoter region of the alpha 1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. Arthritis Rheum 41 (1998) 2048-2058
43. Zhang W., An J., Inagaki Y., et al. Synergistic cooperation between Sp1 and Smad 3/4 mediates transforming growth factor beta 1 stimulation of alpha 2(I) collagen (COL1A2) transcription. J Biol Chem 275 (2000) 39237-39245
44. Felinski E., and Quinn P. The CREB constitutive activation domain interacts with TATA-binding protein-associated factor 110 (TAF110) through specific hydrophobic residues in one of the three subdomains required for both activation and TAF110 binding. J Biol Chem 274 (1999) 11672-11678
45. Coustry F., Sinha S., Maity S., and Crombrugghe B. The two activation domains of the CCAAT-binding factor CBF interact with the dTAF110 component of the Drosophila TFID complex. Biochem J 331 (1998) 291-297
46. Widom R., Culic I., Lee J., and Korn J. Cloning and characterization of hcKrox, a transcriptional regulator of extracellular matrix gene expression. Gene 198 (1997) 407-420
47. Dong C., Zhu S., Wang T., et al. Deficient Smad 7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 99 (2002) 3908-3913
48. Felson D., Anderson J., Boers M., et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 36 (1993) 729-740
49. Felson D., Anderson J., Boers M., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995) 727-735
50. Zarafonetis C. Antifibrotic therapy with Potaba. Am J Med Sci 248 (1964) 550-561
51. Bluestone R., Grahame R., Holloway V., and Holt P. Treatment of systemic sclerosis with D-penicillamine. A new method of observing the effects of treatment. Ann Rheum Dis 29 (1970) 153-158
52. Alarcon-Segovia D., Ramos-Niembro F., Ramos-Niembro G., Alcocer J., and Perez Tamayo R. Long-term evaluation of colchicine in the treatment of scleroderma. J Rheum 6 (1979) 705-712
53. Furst D., Clements P., Harris R., Ross M., Levy J., and Paulus H. Measurement of clinical change in progressive systemic sclerosis: A one-year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis 38 (1979) 356-361
54. Steen V., and Medsger Jr. T. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43 (2000) 2437-2444
55. Steen V., and Medsger Jr. T. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48 (2003) 516-522
56. Furst D., Clements P., Hillis S., et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma: results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 32 (1989) 584-593
57. Beckett V., Conn D., Ruster V., et al. Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum 27 (1984) 1137-1143
58. Blom-Bulow B., Berg K., Wilhelm R., et al. Cyclofenil versus placebo in progressive systemic sclerosis. A one-year double-blind crossover study of 27 patients. Act Med Scand 210 (1981) 419-428
59. Gibson T., and Graham R. Cyclofenil treatment of scleroderma-a controlled study. Br J Rheum 22 (1983) 218-223
60. Williams H., Furst D., Dahl S., et al. Double-blind, multi-center controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. Arthritis Rheum 28 (1985) 308-314
61. Gruber B., and Kaufman L. A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma. Arthritis Rheum 34 (1991) 362-365
62. Casas J., Saway P., Villarreal I., et al. 5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study. Ann Rheum Dis 49 (1990) 926-928
63. Clegg D., Reading J., Mayes M., et al. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. J Rheumatol 21 (1994) 105-120
64. Clements P., Furst D., Wong W., et al. High-dose (HI-DPA) vs low-dose (LO-DPA) penicillamine in early diffuse systemic sclerosis (SSc) trial: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42 (1999) 1194-1203
65. Van den Hoogen F., Boerbooms A., Swaak A., Rasker J., van Lier H., and van de Putte L. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35 (1996) 364-372
66. Pope J., Bellamy N., Seibold J., et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44 (2001) 1351-1358
67. Grassegger A., Schuler G., Hessenberger G., et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 139 (1998) 639-648
68. Black C., Silman A., Herrick A., et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42 (1999) 299-305
69. Badesch D., Tapson V., McGoon M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
70. Rubin L., Badesch D., Barst R., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
71. Oudiz R., Schilz R., Barst R., et al., Treprostinil Study Group. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126 (2004) 420-427
72. Seibold J., Korn J., Simms R., et al. Recombinant human relaxin in the treatment of scleroderma: a randomized double-blind, placebo-controlled multicenter trial. Ann Int Med 132 (2000) 871-879
73. Khanna D., Clements P., Furst D., et al., for the Scleroderma Lung Study Group. Correlation of the degree of dyspnea score correlates with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 52 (2005) 592-600
74. White B., Bauer E., Goldsmith L., et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology committee on design and outcomes in clinical trials in systemic sclerosis. Arthritis Rheum 38 (1995) 351-360
75. Merkel P., Clements P., Reveille J., Suarez-Almazor M., Valentini G., and Furst D. OMERACT 6. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 30 (2003) 1630-1647
76. Steen V. Renal involvement in systemic sclerosis. In: Clements P., and Furst D. (Eds). Systemic sclerosis. 2nd edn. (2004), Lippincott Williams & Wilkins, New York, NY, USA 279-292
77. Badesch D., McLaughlin V., Delcroix M., et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43 12 suppl (2004) 56-61S
78. Galie N., Ghofrani H., Torbicki A., et al., Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) study group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
79. Williams M., DAS C., Handler C., et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005). published online Dec 9. DOI:10.1136/hrt.2005.069484
80. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
81. Ghofrani H., Voswinckel R., Reichenberger F., et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 44 (2004) 1488-1496
82. McLaughlin V., Hill N., Tapson V., et al., on behalf of the STRIDE-1 Study Group. Sitaxentan improves 6MW in patients with pulmonary arterial hypertension (PAH) related to connective-tissue diseases (CTD). Arthritis Rheum 50 (2004) S692
83. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 160 (2000) 1101-1108
84. Wigley F., Wise R., Seibold J., et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120 (1994) 199-206
85. Belch J., Newman P., Drury J., et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet 321 (1983) 313-315
86. Fischer M., Reinhold B., Falck H., Torok M., and Alexander K. Topical nitroglycerin ointment in Raynaud's phenomenon. Z Kardiol 74 (1985) 298-302
87. Franks Jr. A. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet 319 (1982) 76-77
88. Fries R., Shariat K., Von Wilmowsky H., and Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112 (2005) 2980-2985
89. Korn J., Mayes M., Matucci Cerinic M., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 (2004) 3985-3993
90. Seibold J., Denton C., Furst D., et al. Bosentan prevents occurrence but does not speed healing of digital ulcers in patients with systemic sclerosis (SSc). Arthritis Rheum 52 (2005) 4057 (abstr)
91. Clements P., Sterz M., Danovitch G., et al. Cyclosporin (CsA) in systemic sclerosis (SSc): Results of a 48-week open safety study in 10 SSc patients. Arthritis Rheum 36 (1993) 75-83
92. White B., Moore W., Wigley F., Xiao H., and Wise R. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132 (2000) 947-954
93. Clements P., Furst D., Silver R., et al., for the SLS Investigators. The Scleroderma Lung Study (SLS) shows beneficial effects of cyclophosphamide (CYC) over placebo (PL) in Systemic Sclerosis (SSc). Arthritis Rheum 52 (2005) S257
94. Hoyles R., Ellis R., Herrick A., et al. Fibrosing Alveolitis in Scleroderma Trial (FAST)-a multi-centre prospective randomized double-blind placebo-controlled trial. Arthritis Rheum 12 (2005) 4110 (abstr)
95. Farge D., Passweg J., van Laar J., et al. EBMT/EULAR Registry. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 63 (2004) 974-981
96. van Laar J., and Mc Sweeney P. High-dose immunosuppressive therapy and autologous progenitor cell transplantation for systemic sclerosis. Best Pract Res Clin Haematol 17 (2004) 233-245
97. Seibold J. Relaxins: lessons and limitations. Curr Rheumatol Rep 4 (2002) 275-276
98. Ziesche R., Hofbauer E., Wittmann K., Petkov V., and Block L. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341 (1999) 1264-1269
99. King Jr. T., Safrin S., Starko K., et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 127 (2005) 171-177
100. Denton C., Merkel P., Furst D., et al., with CAT-192 Study Group, and SCTC. Anti-TGFβ1 therapy for diffuse cutaneous systemic sclerosis: a multi-center, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 50 (2004) S691 (abstr)